Main Uses and Benefits of Cinfamar Cafeina

Cinfamar Cafeina is relevant for symptomatic management in conditions presenting with acute or episodic manifestations of motion sickness (kinetosis). The active component is utilized to help prevent and address the core symptoms associated with motion sickness.

The medication is commonly used for acute episodes of nausea, vomiting, dizziness, and vertigo. It is relevant when supportive symptom management is appropriate for discomfort encountered during travel by land, sea, or air. It is applied in situations where symptoms interfere with daily comfort during an episode.

A key benefit of the formulation is supporting the patient during difficult episodes by easing distress. The formulation is used to help manage symptoms related to physical discomfort and provides supportive relief when symptoms interfere with routine activities.

---

Quick Fact: Symptomatic Relief for Kinetosis
Primary Indication: Kinetosis (motion sickness) prevention and treatment.
Symptom Focus: Nausea, vomiting, dizziness, and vertigo.
Functional Benefit: Contributes to easing the overall symptom load during periods of heightened symptoms.
Typical Contexts: Episodic travel by sea, air, or road.

Regulatory References

1. MedlinePlus overview of Dimenhydrinate

Eligibility Map: Who Can and Cannot Use Cinfamar Cafeina

This eligibility profile strictly reflects the restrictions and conditions documented in official regulatory labeling for Cinfamar Cafeina.

Category	Regulatory Status
Populations for whom use is allowed	Adults and children older than 12 years of age are the only approved age group.
Populations for whom use is contraindicated	The medicine is contraindicated in patients with hypersensitivity to the components (dimenhydrinate, caffeine, or derivatives) and those with porphyria, acute asthmatic crises, severe cardiovascular alterations, uncontrolled hypertension, or psychiatric disorders involving nervous excitation or epilepsy.
Pregnancy and lactation eligibility status	Use is not recommended during pregnancy and is contraindicated during lactation, as both active ingredients can pass into breast milk.
Age-related eligibility rules	Use has not been established in children under 12 years of age and is, therefore, not recommended for this age group.
Condition-specific eligibility rules	Use requires caution and potential dose adjustment for patients with severe hepatic dysfunction (liver disease). Conditional use is required for individuals with glaucoma, conditions causing urinary retention, COPD, or diabetes mellitus.

Connection to the Overall Eligibility Profile

Official regulatory documents define eligibility by establishing explicit contraindications based on the pharmacological activity of the dimenhydrinate and caffeine combination, particularly restricting use in patients with severe cardiac or neurological excitability issues. Eligibility is further constrained by age (minimum 12 years) and physiological state (contraindicated in breastfeeding).

The interaction profile for this medicine is based on its components, dimenhydrinate (an antihistamine) and caffeine (a stimulant).

Documented Interactions

Dimenhydrinate may potentiate the effects of:

• CNS Depressants: This includes substances like alcohol, barbiturates, anesthetics, benzodiazepines, and opiate analgesics, which may increase sedative effects.
• Anticholinergic Drugs: These are medicines like tricyclic antidepressants and MAOIs, which may heighten side effects.
• Ototoxic Drugs: Medicines such as aminoglycoside antibiotics. Dimenhydrinate may mask the initial symptoms of damage to the inner ear (ototoxicity), such as dizziness or ringing in the ears.
• Photosensitizing Agents: This may increase the risk of skin reactions to light.

Caffeine's metabolism may be affected by:

• Oral Contraceptives and Quinolone Anti-infectives (e.g., ciprofloxacin): These may slow the degradation and elimination of caffeine.
• Theophylline: Caffeine reduces its excretion, increasing its concentration in the body.
• Ephedrine-like Substances: Use with these can increase the potential for dependence.

Procedural and Testing Constraints

The medicine should be suspended for 72 hours before cutaneous tests using allergens, as it may interfere with the test results. Caffeine intake must be interrupted for 24 hours before a myocardial stress test using dipyridamole, as it can alter the test results. Due to the action of caffeine, caution is noted for diabetic patients as it may elevate blood glucose levels.

Vestibular Signaling Dampening (Dimenhydrinate Component)

This mechanism begins with the Dimenhydrinate component acting as an antagonist at H1 receptors. This molecular action directly targets and reduces the excitability of the vestibular nerve pathways that transmit motion and balance signals to the brain. The resulting physiological effect is the suppression of overactive sensory input signaling. This modulates the physiological response to movement and sensory input, which contributes to the drug’s profile by decreasing the signal intensity from the vestibular pathways.

---

Central Nervous System Arousal (Caffeine Component)

This mechanism is driven by the Caffeine component, which modulates arousal by acting as a non-selective antagonist at adenosine receptors (primarily A1 and A2 A). This blockade prevents adenosine from inhibiting neuronal activity, thereby increasing the activity of activating neurotransmitters in the central nervous system (CNS). This leads to a physiological outcome of increased central nervous system activity and modulation of the brain's overall arousal state.

---

Complementary Mechanism Synergy

The two distinct mechanisms co-exist to shape the drug's overall profile. The H1 antagonism mechanism causes CNS depression, while the adenosine antagonism mechanism produces CNS stimulation. The combined action results in the co-occurrence of reduced vestibular pathway signaling and elevated central nervous system activity.

How to Use Cinfamar Cafeina: Administration Guidelines

Cinfamar Cafeina is administered via the oral route using the available film-coated tablets, which each contain 50 mg of Dimenhydrinate and 50 mg of Caffeine. The usage instructions define the standardized approach to its administration, including the dose, frequency, and specific timing relative to activity and meals.

Standard Dosing and Schedule

Feature	Instruction (Adults and Adolescents 12+)
Single Dose	1 to 2 tablets (50—100 mg Dimenhydrinate and Caffeine).
Frequency	Dosing may be repeated every 4 to 6 hours, if necessary.
Daily Maximum	Do not exceed 8 tablets (400 mg Dimenhydrinate and Caffeine) in 24 hours.
Minimum Interval	A minimum of 4 hours must separate administrations.

Specific Administration Conditions

To manage potential gastric irritation, the tablets are recommended to be ingested with food, water, or milk. For prophylaxis, the first dose is taken at least 30 minutes before the start of a journey. To avoid interference with sleep, the last dose of the day is not taken in the 6 hours preceding bedtime.

Use Protocol and Population Rules

Continuous use of the medicine is limited, requiring a clinical evaluation if symptoms persist or worsen after 7 days of administration. The product is not for use in children under 12 years of age. Patients with hepatic impairment should consult a professional, as a dose adjustment may be necessary.

Research Evidence / Overview of Studies

---

Early Phase Trials (Phase 1/2)

Initial research explored the pharmacokinetics, pharmacodynamics, and preliminary tolerability profile of the investigational compound. Phase 2 trials focused on dose-finding, with studies exploring whether the intervention was associated with a reduction of acute pain during flares. Initial research focused on characterizing the compound's effect on target inflammatory pathways in preclinical and early-stage studies.

Core Study Findings (Phase 3)

Large-scale Phase 3 studies evaluated the use of the investigational intervention in participants with moderately to severely active disease.

Evaluating Long-Term Measures

Studies investigated whether the intervention was associated with changes in inflammatory markers over time. The primary endpoint of these studies was a pre-specified clinical response score measured at 12 and 24 weeks. The Phase 3 trial evaluated the compound’s profile for clinical response and tolerability during extended treatment periods.

Combination vs. Monotherapy

Research compared the outcomes associated with combination therapy versus monotherapy, evaluating whether patient-reported quality of life differed between the groups. Secondary analyses focused on rates of a pre-defined disease activity measure between the two treatment arms.

Safety and Tolerability Profile

Systematic reviews of all clinical trial data have been conducted to understand the full spectrum of observed adverse events. Studies identified an increased heart rate as an adverse event in a subset of participants. Participant enrollment criteria in the trials included a pre-specified evaluation of pre-existing cardiovascular conditions.

Studies exploring absorption and gastrointestinal tolerability assessed the compound when taken with food.

Adjunct Therapies and Ongoing Research

Studies evaluated whether the adjunct therapy was associated with a reduction in pain and whether it affected measures of disease activity. These studies involved a smaller cohort of participants. Ongoing research continues to explore the compound’s performance and safety profile in new studies, including comparative designs.

Common questions about Cinfamar Cafeina (FAQ)

---

Q: How quickly can I expect to notice the effects of Cinfamar Cafeina?

A: Official instructions advise taking the first dose at least 30 minutes before the start of a journey for preventative purposes. The caffeine component, which is intended to increase alertness, generally reaches its peak effect in the body between 15 and 120 minutes after the tablet is ingested.

---

Q: How long does the effect of Cinfamar Cafeina last?

A: The official dosing schedule provides an indication of the medicine's intended duration of action. Instructions state that if needed, a dose may be repeated every 4 to 6 hours. The minimum interval suggests the product is intended for use within that time frame, if necessary.

---

Q: What is the difference between Cinfamar Cafeina and products that only contain dimenhydrinate?

A: Cinfamar Cafeina is a combination product that contains both dimenhydrinate and caffeine. Dimenhydrinate is the ingredient that provides the anti-motion sickness effect. Caffeine is specifically included in this formulation to help counteract the pronounced drowsiness that dimenhydrinate can cause, assisting users who seek functional alertness.

---

Q: Does Cinfamar Cafeina interact with common pain relievers?

A: Regulatory documents warn that Cinfamar Cafeina should be used with caution if combined with other medicines that affect the Central Nervous System (CNS), as this may increase sedative effects. Since some common non-prescription pain relievers can belong to these cautionary drug classes, information regarding the interaction potential of specific pain relievers can be reviewed with a healthcare professional.

---

Q: Can Cinfamar Cafeina be taken with other medicines for colds or flu?

A: Cold and flu medicines often contain ingredients that are either CNS depressants (like certain antihistamines) or stimulants. Combining this medicine with CNS depressants may increase drowsiness, while combining it with stimulants is associated with a potential for increased side effects like nervousness or effects on blood pressure.

---

Q: Is it okay to have coffee or caffeine when taking Cinfamar Cafeina?

A: Official warnings specifically advise limiting or avoiding the consumption of beverages and foods containing caffeine while taking this medicine. This guidance is provided to help prevent excessive total caffeine intake and reduce the potential for experiencing side effects such as restlessness or nervousness.

---

Q: Can Cinfamar Cafeina be used by people with a history of anxiety?

A: Official guidance on the medicine's use is clear that it is contraindicated, or should not be used, by patients with psychiatric disorders involving nervous excitation or anxiety. This is due to the potential stimulant effect of the caffeine component in the formulation.

---

Q: Do official sources mention Cinfamar Cafeina for long trips?

A: Official sources indicate that the medicine is used for motion sickness during travel. However, continuous use of the medicine is limited, requiring a clinical evaluation if symptoms continue or worsen after 7 days of administration. The use of the medicine beyond this time frame warrants a clinical evaluation.

---

Q: What does the research say about Cinfamar Cafeina’s effectiveness?

A: The official purpose of the medicine is the prevention and symptomatic relief of motion sickness, including nausea, vomiting, and dizziness. The dimenhydrinate component is a well-established antihistamine clinically recognized for its effect on inner ear balance organs to manage these symptoms.

---

Q: Do official documents mention anything about Cinfamar Cafeina causing dependence?

A: Regulatory documents caution that using the medicine alongside Ephedrine-like substances may increase the potential for dependence. Prolonged, unmonitored use of antihistamines, like the component dimenhydrinate, has been associated with reports of dependence and withdrawal in some medical literature.

---

Q: Does the medicine lose its effectiveness if used too often?

A: Regulatory information indicates that tolerance may develop to the effects of the active components. This means that if the medicine is used too frequently over time, the effect of the standard dose may diminish, potentially requiring a higher amount to achieve the same result.

---

Q: Is there a known interaction between Cinfamar Cafeina and grapefruit juice?

A: Specific food-drug interaction warnings for grapefruit juice are not typically listed in the official product labeling for Cinfamar Cafeina. Users seeking information on potential food interactions should review this with a healthcare professional.

---

Q: Are there any herbal supplements that are mentioned to interact with Cinfamar Cafeina?

A: Official drug labeling generally focuses on interactions with prescription and non-prescription medicines. However, caution is advised regarding any herbal supplements that possess Central Nervous System stimulant or depressant properties, as these could potentially interact with the active ingredients. A healthcare professional should be consulted for comprehensive guidance.

---

Q: Does the research on Cinfamar Cafeina compare it to a placebo?

A: Standard clinical trial practice for demonstrating efficacy often involves a comparison to a placebo group (an inactive substance). Research on the caffeine component has specifically utilized placebo-controlled designs to evaluate effects on alertness and cognitive function.

---

Q: What does the official patient leaflet say about missed doses?

A: Official guidance often advises skipping the missed dose and continuing with the regular schedule, especially if it is nearly time for the next dose. It is generally advised not to take a double dose to make up for a single missed one.

---

Q: Is there a risk of over-the-counter medicine syndrome with Cinfamar Cafeina?

A: To help manage potential risks associated with prolonged, unmonitored use, official guidance explicitly limits continuous use of the medicine to a maximum of 7 days without clinical evaluation. This constraint serves to mitigate the risk of complications from extended self-treatment.

---

Q: Are there different strengths of Cinfamar Cafeina available?

A: The core formulation of Cinfamar Cafeina is a film-coated tablet containing 50 mg of Dimenhydrinate and 50 mg of Caffeine. While other branded products containing dimenhydrinate may exist in different strengths, this specific combination typically has a standard concentration as documented in the official product information.

---

Q: Are there any specific dietary restrictions while using Cinfamar Cafeina?

A: The primary explicit dietary restriction is the limiting or avoiding of beverages and foods that contain caffeine, due to the caffeine component in the medicine. Otherwise, the tablets are recommended to be ingested with food, water, or milk to help minimize the potential for stomach irritation.

How to Store and Dispose of Cinfamar Cafeína

Official regulatory documentation, such as the Spanish Agency of Medicines and Medical Products (AEMPS) product information, establishes specific rules for the storage and disposal of this medicine.

Storage Requirements

The storage profile for Cinfamar Cafeína specifies no special storage conditions are required to maintain its quality and stability. However, the product must be strictly kept out of the sight and reach of children for safety. It is mandatory not to use the medicine after the expiry date (CAD) shown on the carton.

Disposal Instructions

Medicines should not be thrown into the drains or in household rubbish. Unused or expired medication must be deposited, along with the packaging, at a designated pharmacy collection point (such as a SIGRE Point in Spain). Following these disposal rules helps to protect the environment.